[{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CRLX101","moa":"DNA topoisomerase I (TOP1)","graph1":"Oncology","graph2":"Phase I","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CRLX101","moa":"DNA topoisomerase I (TOP1)","graph1":"Oncology","graph2":"Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"CRLX101","moa":"DNA topoisomerase I (TOP1)","graph1":"Oncology","graph2":"Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"CRLX101","moa":"DNA topoisomerase I (TOP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Idarubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Algenpantucel-L","moa":"Galactosyltransferase (GALT)","graph1":"Oncology","graph2":"Phase III","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Hyperacute-Melanoma","moa":"Immune system (antigen presentation)","graph1":"Oncology","graph2":"Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Hyperacute-Renal","moa":"Immune system (antigen presentation)","graph1":"Oncology","graph2":"Phase I","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"NLG802","moa":"Indoleamine 2,3-dioxygenase 1 (IDO1)","graph1":"Oncology","graph2":"Phase I","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CRLX301","moa":"mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Indoximod","moa":"mTORC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Indoximod","moa":"mTORC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Indoximod","moa":"mTORC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Indoximod","moa":"mTORC1","graph1":"Undisclosed","graph2":"Phase I","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"RNA | DNA | Thymidylate synthase||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"},{"orgOrder":0,"company":"NewLink Genetics Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Indoximod HCl","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"NewLink Genetics Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewLink Genetics Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NewLink Genetics Corporation \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by NewLink Genetics Corporation
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
